Related Experiment Video
Updated: Jan 9, 2026

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
Genotype-phenotype correlations of GFAP variants in type I Alexander disease subtypes
Tiziana Bachetti1, Ylenia Vaia2, Alice Grossi3
1UO Proteomica e Spettrometria di Massa, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Specific Glial Fibrillary Acidic Protein (GFAP) variants correlate with disease progression in Alexander disease (AxD) Type I. This finding aids in sub-classifying patients and managing the rare leukodystrophy.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alexander disease (AxD) is a rare, progressive leukodystrophy linked to Glial Fibrillary Acidic Protein (GFAP) gene variants.
- Type I AxD exhibits variable progression, necessitating sub-classification into subtypes Ia, Ib, Ic, and Id.
- Understanding genotype-phenotype correlations is crucial for predicting disease trajectory.
Purpose of the Study:
- To investigate genotype-phenotype correlations in Type I Alexander disease across its clinical subtypes (Ia-Id).
- To identify specific GFAP variants associated with disease progression and ambulation milestones.
- To explore the functional impact of GFAP variants on intermediate filament assembly.
Main Methods:
- Analyzed a cohort of 74 genetically confirmed Type I AxD patients, categorized by subtypes Ia-Id.
- Explored genotypic-phenotypic correlations, stratifying by independent ambulation achievement.
- Performed in vitro assays to assess the assembly of selected mutant GFAP proteins.
Main Results:
- Observed a decrease in GFAP allelic heterogeneity from subtype Ia to Id.
- GFAP variants in exon 1 correlated with milder forms, while exon 4 mutations indicated severe phenotypes.
- Specific variants at p.R239 and p.R79 residues showed distinct trends across subtypes and correlated with ambulation ability.
Conclusions:
- Specific GFAP variants may predict disease progression in Type I AxD.
- These findings support improved patient sub-classification and personalized management strategies.
- Considering genetic and clinical factors is vital for advancing AxD therapeutics.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Genetic Lingo
Pleiotropy
Incomplete Dominance